Market Signal Briefing

TL;DR:

Bitcoin could reach $250,000 driven by institutional adoption and a possible strategic reserve. Solana projects growth toward $500 thanks to its ETF ecosystem and asset tokenization. XRP has the potential to scale up to $10 after overcoming its main legal barriers. DeepSeek’s cryptocurrency predictions were recently revealed, outlining a highly bullish scenario for the end of 2026. The AI’s analysis reveals that clearer regulation in the United States and the continuity of the bull market could lead major assets to historic records.

Regarding Bitcoin, the AI suggests that the long-term trend will remain intact despite recent corrections caused by geopolitical tensions. It is estimated that the pioneer cryptocurrency could scale up to $250,000, consolidating itself as a hedge against inflation and a reserve asset for large institutions.

Projections for Major Altcoins and the Rise of Solana Solana is positioned as one of the most robust ecosystems due to its growth in total value locked (TVL) and increasing developer activity. In its forecast, DeepSeek points out that SOL could exceed $500, driven by the success of its ETFs and its fundamental role in traditional financial infrastructure.

As for XRP, the AI highlights its leadership in the institutional cross-border payments sector and estimates a price target of up to $10 for next year. This growth would be backed by Ripple’s legal victory and the implementation of a comprehensive regulatory framework that removes uncertainty surrounding the token.

Finally, the analysis does not ignore the memecoin segment, mentioning Maxi Doge ($MAXI) as one of the most talked-about presales of 2026. Consequently, the overall outlook suggests that, if institutional catalysts are maintained, the crypto ecosystem will experience an unprecedented expansion phase in the coming months.

In brief IREN and CleanSpark shares fell sharply after both companies missed revenue estimates in their latest earnings reports. The results landed as Bitcoin contines its slide, amplifying pressure on publicly traded miners. Investors appeared focused on near-term execution and balance-sheet risk despite both companies’ push into AI infrastructure. Publicly traded Bitcoin miners IREN and CleanSpark saw their share prices drop sharply on Thursday, as disappointing quarterly results coincided with a broader crash across cryptocurrency markets.

CleanSpark shares closed sharply lower, falling $1.95, around 19%, on the session, and were trading at $7.55 in after-hours trading. IREN shares fell $5.11, or 11%, during the day and were trading at $32.42 after the close, according to MarketWatch.

The downturn underscores the ongoing financial volatility for miners and investors as they navigate fluctuating asset prices and infrastructure expenses.

IREN reported $184.7 million in revenue for its fiscal second quarter ended December 31, 2025, down from $240.3 million in the prior quarter. The company posted a net loss of $155.4 million, reversing $384.6 million in net income reported in the previous period.

The company said the quarter reflected a transition as it shifts from Bitcoin mining toward AI cloud infrastructure.

Results included significant non-cash and non-recurring items, including $219.2 million in unrealized losses tied to financial instruments and a one-time debt conversion inducement expense, as well as $31.8 million in mining hardware impairments related to an ongoing ASIC-to-GPU transition across its British Columbia operations.

Even though the company's stock slid, Daniel Roberts, co-founder and co-CEO of IREN, said the company continued to make progress during the quarter as it expanded its AI cloud business.

“Last quarter marked meaningful progress across capacity expansion, customer engagement, and capital formation, reflecting IREN’s progress as a scaled AI Cloud platform,” Roberts said in a statement on X.

CleanSpark also reported quarterly results that fell short of expectations. The company posted $181.2 million in revenue for the quarter ended December 31, 2025, up from a year earlier, but reported a net loss of $378.7 million, compared with net income in the same quarter last year.

CleanSpark said the loss was driven largely by non-cash items tied to Bitcoin price movements and asset revaluations. As of quarter-end, the company reported $458 million in cash, $1 billion in Bitcoin holdings, and $1.3 billion in working capital, alongside $1.8 billion in long-term debt.

The earnings reports landed during a broad selloff across cryptocurrency markets, with Bitcoin falling more than 11% on the day.

The decline has weighed on publicly traded miners and other crypto-exposed companies, increasing scrutiny of earnings volatility and balance-sheet exposure.

Despite the sell-off, CleanSpark President and CFO Gary A. Vecchiarelli tried to paint an optimistic picture.

"Bitcoin mining generates the cash flow, AI infrastructure monetizes the assets over the long term, and our Digital Asset Management function optimizes capital and liquidity across cycles.," he wrote on X. "This approach gives us flexibility and provides the framework to allocate capital where returns are most attractive, a combination we believe is increasingly rare in today’s market.”

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

U.S.-Iran warning resurfaces ahead of nuclear talks, further pressuring bitcoin and crypto markets Feb 6, 2026, 3:27 a.m.

A U.S. advisory urging American citizens to “leave Iran now” is circulating again online, adding another layer of headline risk to a crypto market already wobbling on high volatility and forced liquidations.

🚨BREAKING: The US Governments tells its citizen to LEAVE IRAN IMMEDIATELY. Could this be why the markets nuked today? Are we going to war? pic.twitter.com/ZmnGDSUJcf

— Autism Capital 🧩 (@AutismCapital) February 6, 2026 STORY CONTINUES BELOW

Officials have since clarified the warning itself is not new and was first issued in mid-January. Still, the timing matters. The advisory is resurfacing just as the U.S. and Iran prepare to hold nuclear talks in Oman on Friday, with President Donald Trump publicly warning Iran’s Supreme Leader Ayatollah Ali Khamenei and Tehran threatening retaliation if attacked.

For crypto traders, the immediate takeaway is not whether the advisory is fresh. It’s that the market is behaving like a fragile, leveraged macro trade. In this kind of environment, geopolitical headlines tend to hit bitcoin the same way they hit high-beta tech stocks, not the way they hit gold.

Bitcoin has already been swinging wildly after a week of liquidation-driven selling, and the market’s sensitivity is elevated. When positioning is stretched and liquidity is thin, even ambiguous news can trigger rapid deleveraging, especially in perpetual futures.

The asset has repeatedly sold off whenever geopolitical drama makes headlines, with investors preferring the perceived safety of gold or bonds against digital assets.

The Iran headlines may ultimately fade, especially if the Oman talks proceed smoothly. But in a market that is still digesting heavy losses and where sentiment is already brittle, traders are likely to treat geopolitics as a volatility accelerant rather than a directional catalyst.

Solana memecoin launchpad Pump.fun has acquired trading execution terminal Vyper in its latest strategic expansion.

In a post on X on Thursday, Vyper wrote that Pump.fun had officially acquired Vyper, adding that its team and tech will now join Pump.fun's broader product suite.

"Vyper's infrastructure will soon be migrated to [Terminal]," the team said. "As part of that process, Vyper will soon be sunsetting."

The Vyper acquisition builds on Pump.fun's earlier push into trading infrastructure. In October 2025, Pump.fun acquired Padre and later rebranded it as Terminal — a multichain trading platform focusing on memecoins and high-speed execution.

"EVM support is a core focus for Terminal. With Vyper's infrastructure & talent, expect trading on EVM (including Base) to massively improve," the Terminal team said Thursday on X.

Pump.fun co-founder Alon Cohen described the Vyper acquisition as part of a broader expansion strategy, even as market conditions remain challenging. "Despite market conditions, we're expanding our team rapidly and aggressively," Cohen wrote on X. 

Cohen said the addition of Vyper team members with experience in onchain trading would strengthen Pump.fun's ability to build "super rapid and efficient cross-chain trading infrastructure," which he said would be critical as the company continues investing in its core platform, its mobile app, and Terminal.

Neither Pump.fun nor Vyper has disclosed financial details of the deal. The Block has reached out to both teams for further information.

Pump.fun continues to evolve its services, including its incentive structure. Earlier this month, the company overhauled its creator fee model to introduce broader revenue sharing, allowing teams to split fees across up to 10 wallets, transfer coin ownership and revoke update authority.

The platform has also seen a renewed surge in activity. According to The Block's data, nearly 30,000 tokens were launched on Pump.fun on Feb. 2, compared with roughly 9,000 to 13,000 daily launches in early October 2025.

Disclaimer: The Block is an independent media outlet that delivers news, research, and data. As of November 2023, Foresight Ventures is a majority investor of The Block. Foresight Ventures invests in other companies in the crypto space. Crypto exchange Bitget is an anchor LP for Foresight Ventures. The Block continues to operate independently to deliver objective, impactful, and timely information about the crypto industry. Here are our current financial disclosures.

© 2026 The Block. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Asia Market Open: Bitcoin Plunge to $64K Rattles Risk Assets as Tech Slump Ripples Through Asia

Shalini Nagarajan

Crypto Reporter

Shalini Nagarajan

Part of the Team Since

Jan 2024

About Author

Shalini is a crypto reporter who provides in-depth reports on daily developments and regulatory shifts in the cryptocurrency sector.

Has Also Written

Last updated: 

15 minutes ago

Bitcoin tumbled more than 10% toward $64,000, extending a brutal week for crypto as selling pressure spread across risk assets and shook markets from New York to Asia.

The drop dragged Bitcoin to its weakest level since late 2024, reversing momentum that had built after Donald Trump’s election win, when he signalled a more supportive stance on crypto during the campaign trail.

Crypto losses came as investors dumped tech stocks and even safe-haven trades turned jumpier. Volatility in precious metals also picked up, as leveraged bets and speculative flows amplified price swings.

Market snapshot Bitcoin: $64,798, down 9.2% Ether: $1,900, down 9.7% XRP: $1.27, down 12.4% Total crypto market cap: $2.29 trillion, down 8.2% ETF Outflows Mount As Crypto Selloff Deepens Into FebruaryCoinGecko data showed the global crypto market has lost about $2 trillion in value since its October peak, with roughly $800B erased over the past month. Bitcoin was down about 17% for the week and roughly 28% for the year so far, while Ether was headed for a 19% weekly slide and a 38% drop year-to-date.

Traders also kept an eye on the plumbing of the rally that powered crypto higher last year, especially flows into exchange-traded funds.

Analysts from Deutsche Bank said in a note that US spot Bitcoin ETFs witnessed outflows of more than $3B in January, following outflows of about $2B and $7B in December and November, respectively.

Deutsche Bank: Bitcoin’s selloff signals a loss of conviction, not a broken market.

➥ BTC’s decline is driven by ETF outflows, weaker liquidity, and slower regulatory progress — a gradual erosion of trust, not a macro shock

➥ Bitcoin has decoupled from gold and equities.…

— BTC Live (@btcliveco) February 5, 2026 Akshat Siddhant, lead quant analyst at Mudrex, said currently bears remain in control of the crypto market.

“The recent decline was driven by softer US labour data and growing concerns around heavy capital spending in the AI sector, which weighed on broader risk sentiment,” he said.

“Continued ETF outflows and short-term holders moving nearly 60,000 BTC to exchanges have added to near-term selling pressure. That said, for long-term investors, this phase offers a favourable accumulation opportunity through disciplined, staggered buying.”

Matt Howells Barby, VP at Kraken, said Bitcoin’s recent tumble doesn’t rule out further short-term downside.

“Price is now entering a well-defined support zone between $54,000 and $69,000, but the weekly RSI has dipped below 30 for the first time since mid-2022 — a signal that has historically preceded major bottoms forming within a three-to-six-month window,” he said.

“In our view, a base is most likely to form in the $54,000–$60,000 range, particularly as the low-$50,000s align with the 200-day moving average.”

Risk Appetite Fades As Labour Data And Tech Losses CombineIn Asia, the risk-off mood hit equities early. MSCI’s broadest index of Asia-Pacific shares outside Japan fell about 1%, led by a 5% dive in South Korea’s Kospi that triggered a brief trading halt shortly after the open, and Japan’s Nikkei 225 also slipped.

US stock futures pointed lower too, after Wall Street ended sharply down overnight as tech heavyweights fell and investors questioned whether massive AI spending would translate into near-term profits.

Alphabet added to the anxiety after saying it could lift 2026 capital spending as high as $185B, part of an AI arms race that has investors watching cash burn as closely as revenue growth.

Fresh labour market signals also fed the unease, with a report showing US layoffs announced by employers surged in January to the highest level for the month in 17 years, reinforcing a broader pullback in risk appetite.

Monolithic Power Systems, Inc. (MPWR) Q4 2025 Earnings Call February 5, 2026 5:00 PM EST

Company Participants

Arthur Lee - Finance Manager
Tony Balow - Vice President of Finance
Bernie Blegen - Executive VP & CFO
Michael R. Hsing - Founder, Chairman, President & CEO

Conference Call Participants

Christopher Caso - Wolfe Research, LLC
Joseph Quatrochi - Wells Fargo Securities, LLC, Research Division
Joshua Buchalter - TD Cowen, Research Division
Quinn Bolton - Needham & Company, LLC, Research Division
Richard Schafer - Oppenheimer & Co. Inc., Research Division
Gary Mobley - Loop Capital Markets LLC, Research Division
Tore Svanberg - Stifel, Nicolaus & Company, Incorporated, Research Division
Wei Chia - Citigroup Inc. Exchange Research
Jack Egan - Charter Equity Research
Sebastien Cyrus Naji - William Blair & Company L.L.C., Research Division

Presentation

Arthur Lee
Finance Manager

Welcome, everyone, to the MPS Fourth Quarter 2025 Earnings Webinar. My name is Arthur Lee, and I'll be the moderator for this webinar. Joining me today are Michael Hsing, CEO and Founder of MPS; Bernie Blegen, EVP and CFO; Rob Dean, Corporate Controller; and Tony Balow, Vice President of Finance.

Earlier today, along with our earnings announcement, MPS released a written commentary on the results of our operations. Both documents can be found on our website. Before we begin, I would like to remind everyone that in the course of today's presentation, we may make forward-looking statements and projections within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties.

The risks, uncertainties and other factors that could cause actual results to differ from these forward-looking statements are identified in the safe harbor statements contained in the Q4 2025 earnings release, our Q4 2025 earnings commentary and in our SEC filings, including our Form 10-K and Forms 10-Q, which can be found on our website. Our statements are made as of today, and we assume

RENK Group AG (RKGRY) Discusses Pre-Close Operational Performance and Order Intake Ahead of FY 2025 Results Transcript

New York, New York--(Newsfile Corp. - February 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gauzy Ltd. (NASDAQ: GAUZ) between March 11, 2025 and November 13, 2025, both dates inclusive (the "Class Period"), of the important February 6, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Gauzy securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Gauzy class action, go to https://rosenlegal.com/submit-form/?case_id=48715 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) three of Gauzy's French subsidiaries lacked the financial means to meet their debts as they became due; (2) as a result, it was substantially likely insolvency proceedings would be commenced; (3) as a result, it was substantially likely a potential default under Gauzy's existing senior secured debt facilities would be triggered; and (4) as a result of the foregoing, defendants' positive statements about Gauzy's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Gauzy class action, go to https://rosenlegal.com/submit-form/?case_id=48715 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282950

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

, /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This latest designation applies to ivonescimab in combination with chemotherapy for the first-line treatment of advanced biliary tract cancer (BTC).

This milestone represents the fifth BTD awarded to ivonescimab by the NMPA, following three prior designations in lung cancer indications and one for triple-negative breast cancer (TNBC). The repeated recognition highlights ivonescimab's broad clinical potential across multiple high unmet need tumor types.

A randomized, controlled, multicenter, registrational Phase III clinical study (AK112-309/HARMONi-GI1) is evaluating ivonescimab plus chemotherapy versus durvalumab (a PD-L1 inhibitor) plus chemotherapy for first-line treatment of advanced BTC. Patient enrollment has been completed, and the BTD status for this indication underscores the promising clinical profile of ivonescimab. The BTD status is expected to accelerate both the ongoing clinical development and the regulatory review process in China.

Encouraging results from a Phase 1b/II study, presented at the 2024 American Society of Clinical Oncology (ASCO) Annual meeting, support the potential of the ivonescimab combination therapy as a superior first-line treatment for advanced BTC. In the study, ivonescimab plus chemotherapy achieved an Objective Response Rate (ORR) of 63.6% and a Disease Control Rate (DCR) of 100%. The ivonescimab regimen also demonstrated a median Progression-Free Survival (mPFS) of 8.5 months and a median Overall Survival (mOS) of 16.8 months.

These compelling Phase II results provide a robust foundation for the ongoing Phase III registrational trial and reinforce ivonescimab's potential to address the significant unmet needs in advanced BTC, where current treatment options often yield limited durable responses.

Forward-Looking Statement of Akeso, Inc.
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 26 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.

Akeso Contacts:
Media: [email protected]
Investors: [email protected]

SOURCE Akeso, Inc.

For the quarter ended December 2025, Werner Enterprises (WERN - Free Report) reported revenue of $737.64 million, down 2.3% over the same period last year. EPS came in at $0.05, compared to $0.08 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $770.01 million, representing a surprise of -4.2%. The company delivered an EPS surprise of -45.18%, with the consensus EPS estimate being $0.09.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Werner performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Operating Ratio: 104.9% versus 97.3% estimated by three analysts on average.Truckload Transportation Services - Operating Ratio: 106.4% compared to the 97.1% average estimate based on three analysts.Dedicated - Average trucks in service: 4,954 versus the two-analyst average estimate of 4,851.One-Way Truckload - Average percentage of empty miles: 16.2% versus the two-analyst average estimate of 15.7%.One-Way Truckload - Average % change YOY in revenues per total mile: -0.1% versus 1.4% estimated by two analysts on average.Revenues- Werner Logistics: $207.54 million compared to the $232.35 million average estimate based on three analysts. The reported number represents a change of -2.6% year over year.Revenues- Truckload Transportation Services- Trucking fuel surcharge revenues: $57.4 million compared to the $57.65 million average estimate based on three analysts. The reported number represents a change of -0.3% year over year.Revenues- Truckload Transportation Services: $512.64 million versus the three-analyst average estimate of $520.65 million. The reported number represents a year-over-year change of -2.8%.Revenues- Truckload Transportation Services- Non-trucking and other: $7.77 million compared to the $9.8 million average estimate based on three analysts. The reported number represents a change of -29.5% year over year.Revenues- Truckload Transportation Services- Trucking revenues, net of fuel surcharge: $447.47 million versus $453.19 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -2.5% change.Trucking revenues, net of fuel surcharge- Dedicated: $291.62 million compared to the $296.88 million average estimate based on two analysts. The reported number represents a change of +1% year over year.Trucking revenues, net of fuel surcharge- One-Way Truckload: $155.85 million compared to the $154.76 million average estimate based on two analysts. The reported number represents a change of -8.3% year over year.View all Key Company Metrics for Werner here>>>

Shares of Werner have returned +17.3% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

By PYMNTS  |  February 5, 2026

 | 

Amazon’s Q4 earnings call on Thursday (Feb. 5) produced the number everyone repeated: CEO Andy Jassy said Amazon expects to invest about $200 billion in capital expenditures in 2026, “predominantly in AWS,” to add capacity for AI and core cloud workloads.

But the call wasn’t only an AI-capex story. It also previewed how Amazon wants to use that infrastructure to make shopping faster and more frequent across Stores and grocery.

Jassy described the moment as something bigger than a typical tech cycle.

“As fast as we install this capacity, this AI capacity, we are monetizing it,” he told the company’s Q4 earnings call audience. “So it’s just a very unusual opportunity. I passionately believe that every customer experience that we know of today is going to be reinvented with AI … [and] if you really want to use AI in an expansive way, you need your data in the cloud and you need your application in the cloud.”

From there, the conversation shifted to what that means outside the data center. Amazon’s consumer pitch is still classic: broad selection, sharp prices and fast delivery. What’s changing is the interface. Amazon is betting that “agentic” AI will become a major way people shop.

On the enterprise side, Jassy said “the primary way companies will get value from AI is with agents,” and he emphasized the gating factor is trust. Agents have to connect to data and tools with controls around identity, policy and governance. On the retail side, those ideas show up in Rufus, Amazon’s shopping assistant. “We have 300 million customers who used Rufus in 2025,” Jassy said, adding that “customers who used Rufus are about 60% more likely to complete a purchase.”

Advertisement: Scroll to Continue

Rufus can research products, track prices and auto-buy when an item hits a customer-set price. It can also shop tens of millions of items in other online stores and make purchases using its agentic Buy For Me feature.

Essential Groceries Then Jassy turned to the retail driver he kept returning to: everyday essentials and grocery.

“In 2025, Everyday Essentials grew nearly twice as fast as all other categories in the U.S., representing 1 out of every 3 units sold in our store, and we’ve become a go-to grocery destination for over 150 million Americans, mostly through online shopping at Whole Foods,” he said. “With over $150 billion in gross sales, Amazon is clearly a large grocer at this point.”

The delivery piece matters. Amazon said customers in thousands of U.S. cities and towns can get perishables delivered same day alongside millions of other items and Jassy noted that shoppers who use same-day grocery shop more than twice as often as those who don’t. He also said Amazon plans to expand grocery delivery further in 2026 and “open more than 100 new Whole Foods Market stores over the next few years” as it works to make grocery shopping “easier, faster and more affordable.”

Three Other Call Moments Worth Watching

Delivery speeds: Amazon said 2025 was its fastest-ever year for Prime delivery globally. In the U.S., it delivered nearly 70% more items same day than the year before. Jassy highlighted “Add to Delivery,” a one-tap feature that already represents about 10% of weekly U.S. Prime volume fulfilled through Amazon’s network. OpenAI relationship: Jassy called Amazon’s OpenAI agreement “a big one” and said Amazon hopes to “continue to extend our partnership over time,” while stressing the AI boom will spread across thousands of companies, not just “a couple.” Robotics: Jassy said Amazon has “over a million robots” in its fulfillment network today, positioning automation as a lever to lower cost-to-serve (and reduce repetitive work) as delivery speeds keep rising. Amazon closed the quarter with net sales of $213.4 billion, up 14% year over year (12% excluding foreign exchange). North America revenue was $127.1 billion (+10%), International revenue was $50.7 billion (+17% reported), and AWS revenue was $35.6 billion (+24%). Operating income rose to $25 billion (including about $2.4 billion of special charges), and net income was $21.2 billion, or $1.95 per diluted share. Trailing 12‑month free cash flow was $11.2 billion.

-

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Ultragenyx who were adversely affected by alleged securities fraud between August 3, 2023 and December 26, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-rare/

Ultragenyx investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-rare/ to learn more.

CASE DETAILS: On December 26, 2025, the Company announced the “results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta” disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company “is evaluating its planned operations and will promptly define and implement significant expense reductions.” On this news, the price of Ultragenyx’s shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.

The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.

WHAT TO DO? If you invested in Ultragenyx and suffered a loss during the relevant time frame, you have until April 6, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

More News From Kahn Swick & Foti, LLC

Back to Newsroom

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. (NYSE: PFSI) resulting from allegations that PennyMac may have issued materially misleading business information to the investing public.

So What: If you purchased PennyMac securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=51887 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On January 29, 2026, PennyMac filed a Current Report with the Securities Exchange Commission on Form 8-K announcing PennyMac's fourth quarter and full-year 2025 financial results. The report stated that PennyMac's "servicing segment pretax income was $37.3 million, down from $157.4 million in the prior quarter and $87.3 million in the fourth quarter of 2024," as well as "[retax income excluding valuation-related items was $47.8 million, down 70 percent from the prior quarter driven primarily by increased realization of mortgage servicing rights (MSR) cash flows as lower mortgage rates drove higher prepayment activity."

On this news, PennyMac's stock price fell $49.78 per share, or 33.3%, to close at $99.92 per share on January 30, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Viasat, Inc. (VSAT) Q3 2026 Earnings Call February 5, 2026 5:30 PM EST

Company Participants

Lisa Curran - Vice President of Investor Relations
Mark Dankberg - Co-Founder, Chairman & CEO
Garrett Chase - Senior VP & CFO

Conference Call Participants

Brent Penter - Raymond James & Associates, Inc., Research Division
Sebastiano Petti - JPMorgan Chase & Co, Research Division
Ryan Koontz - Needham & Company, LLC, Research Division
Michael Crawford - B. Riley Securities, Inc., Research Division
Xin Yu - Deutsche Bank AG, Research Division
Justin Lang - Morgan Stanley, Research Division

Presentation

Operator

My name is Jordan, and I'll be your conference facilitator this afternoon. At this time, I'd like to welcome everyone to Viasat's Third Quarter Fiscal Year 2026 Earning Results Conference Call. [Operator Instructions]

I'd now like to turn the call over to Ms. Lisa Curran, SVP of Investor Relations. Ms. Curran, you may begin the conference.

Lisa Curran
Vice President of Investor Relations

Thank you, Jordan. We will present certain non-GAAP financial measures on today's call. Information required by the SEC relating to these non-GAAP financial measures is available in our Q3 Fiscal year 2016 (sic) [ 2026 ] shareholder letter on the Investor Relations section of our website.

During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. We will also make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we expect or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, and actual results might differ materially from any forward-looking statements that we make today.

Information regarding these factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings and Annual Report on Form 10-K. These

SANTA ANA, CA / ACCESS Newswire / February 5, 2026 / Infinity Bancorp (OTCQB:INFT) (the "Company" or "Bancorp"), the holding company for Infinity Bank (the "Bank"), today announced the approval of a quarterly cash dividend by its Board of Directors. The Board of Directors declared a cash dividend of $0.09 per common share, payable March 6, 2026 to shareholders of record on February 20, 2026.

Infinity Bank is the sole subsidiary of Infinity Bancorp. Infinity Bancorp, formed on October 21, 2022, is the bank holding company for Infinity Bank. The Bancorp does not have any operations other than through its sole subsidiary, Infinity Bank. The Bank is a community bank that commenced operations in February 2018. The Bank is focused on serving the banking needs of commercial businesses, professional service entities, their owners, employees, and families. The Bank offers a broad selection of depository products and services as well as business loan and commercial real estate financing products uniquely designed for each client. For more information about Infinity Bank and its services, please visit the website at www.infinity.bank

6 Hutton Centre Drive, Suite 100
Santa Ana, CA 92707

SOURCE: Infinity Bank Santa Ana California

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Danone S.A. ("Danone" or the "Company") (OTCMKTS: DANOY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Danone and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On January 21, 2026, Reuters reported Danone was "recalling and blocking batches of infant milk formula after a contamination scare." Specifically, cereulide, a potent cytotoxin, had been detected in Danone's Thai-origin Dumex Dulac 1. 

On this news, Danone's American Depositary Receipt ("ADR") price fell $1.37 per ADR, or 7.95%, to close at $15.87 per ADR on January 21, 2026. 

Then, on January 23, 2026, Danone issued a press release announcing a recall of select batches of its infant formula "to comply with the latest guidance." 

On this news, Danone's ADR price fell $0.43 per ADR, or 2.7%, to close at $15.55 per ADR on January 23, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Apollo Global Management, Inc. ("Apollo" or the "Company") (NYSE: APO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Apollo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On February 1, 2026, the Financial Times reported that "Top Apollo Global Management executives including chief Marc Rowan held wide-ranging discussions over the firm's tax arrangements with Jeffrey Epstein throughout the 2010s, despite the private capital firm having previously said it 'never did any business' with" Epstein. 

On this news, Apollo's stock price fell $7.69 per share, or 5.72%, to close at $126.85 per share on February 3, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

There's another fight brewing around GLP-1 drugs -- this time on the delivery side.

The headline-grabbing battle in the GLP-1 space pits pharmaceutical giants Eli Lilly (LLY 7.82%) and Novo Nordisk (NVO 8.18%) against each other. That makes sense, since they both make GLP-1 drugs.

However, another battle is brewing that could be even larger, as Amazon (AMZN 4.36%) starts selling GLP-1 pills, competing with sellers like Hims & Hers (HIMS 3.67%), WW International (WW 6.42%), and GoodRx (GDRX +4.98%).

The big development in GLP-1 drugs Up until 2026, GLP-1 weight loss drugs were only available in injection form. The first company to market was Novo Nordisk with its Wegovy drug. However, Eli Lilly's Mounjaro and Zepbound quickly took the lead after introducing their injectable versions.

Image source: Getty Images.

In 2026, Novo Nordisk was again first to market, this time with a pill version of Wegovy. Consumers generally prefer taking a pill to injecting themselves. Although Eli Lilly is working on its own GLP-1 pill, Novo Nordisk has a chance to regain some market share while it remains the only GLP-1 provider with a pill.

The opportunity here, however, may extend well beyond drug stocks. With a pill, there's a high likelihood that more consumers will be willing to take GLP-1 drugs to help them on their weight loss journey.

Amazon sees an opportunity This helps explain why Amazon is happily offering the pill version of Wegovy to its customers. The cost could be as low as $25 for a one-month supply for those with insurance and as little as $149 for those without insurance.

Today's Change

(

-4.36

%) $

-10.16

Current Price

$

222.82

Hims & Hers, WW International, and GoodRx will be in the same price range because they'll have to be if they want to compete. Notably, WW stands out for its holistic approach to weight loss, which goes well beyond just filling a prescription. But Amazon has an edge because of its large customer base, built-in advertising platform, and the ease with which consumers can buy from the company.

All will benefit, but one may benefit more The truth is that every company selling GLP-1 drugs, in pill form or shot form, is likely to benefit from increased demand. However, Amazon could end up taking material market share on the retail side because of its roughly 200 million Prime members. Simply put, it has a massive reach in the e-commerce space, and converting that into GLP-1 sales shouldn't be all that difficult. Hims & Hers, WW International, and GoodRx could all face a severe competitive disadvantage if GLP-1 pills lead to mass adoption of weight loss drugs.

Posting strong Q4 results yesterday evening, Alphabet (GOOGL) stock still dipped half a percentage point in Thursday's trading session as investors pondered its massive spending plans.

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Tandem Diabetes securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=19024 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On August 7, 2025, before the market opened, the company issued a press release entitled “Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps.” The release stated that Tandem Diabetes had “announced a voluntary medical device correction for select t:slim X2 insulin pumps to address a potential speaker-related issue that can trigger an error resulting in a discontinuation of insulin delivery.”

On this news, Tandem Diabetes’ stock fell 19.9% on August 7, 2025.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Gen Digital Inc. (GEN) Q3 2026 Earnings Call February 5, 2026 5:00 PM EST

Company Participants

Jason Starr - Head of Investor Relation
Vincent Pilette - Chairman & CEO
Natalie Derse - Chief Financial Officer

Conference Call Participants

Roger Boyd - UBS Investment Bank, Research Division
Meta Marshall - Morgan Stanley, Research Division
Matthew Hedberg - RBC Capital Markets, Research Division
Saket Kalia - Barclays Bank PLC, Research Division
Robert Coolbrith - Evercore ISI Institutional Equities, Research Division
Joseph Gallo - Jefferies LLC, Research Division

Presentation

Operator

Good afternoon, everyone. Thank you for standing by. My name is Tamia, and I will be your conference operator today. Today's call is being recorded [Operator Instructions] At this time, for opening remarks, I would like to pass the call over to Jason Starr, Head of Investor Relations.

Jason Starr
Head of Investor Relation

Thank you, Tamia, and good afternoon, everyone. Welcome to Gen's Third Quarter Fiscal Year 2026 Earnings Call. Joining me today are Vincent Pilette, CEO; and Natalie Derse, CFO.

As a reminder, there will be a reminder of this call posted on the Investor Relations website along with our slides and press release. I'd like to remind everyone that during this call, all references to the financial measures are non-GAAP, and all growth rates are year-over-year unless otherwise stated. A reconciliation of non-GAAP to GAAP measures is included in our press release and earnings presentation. both of which are available on our IR website at investor.gendigital.com. We encourage investors to monitor this website as we routinely post investor-oriented information such as news and events and financial filings.

Today's call contains statements regarding our business, financial performance and operations, including the impact on our business and industry that may be considered forward-looking statements, and such statements involve risks and uncertainties that may cause actual results to differ materially from

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integer Holdings Corporation (NYSE: ITGR) between July 25, 2024 and October 22, 2025, both dates inclusive (the “Class Period”), of the important February 9, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Integer common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Integer class action, go to https://rosenlegal.com/submit-form/?case_id=49170 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 9, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Integer materially overstated its competitive position within the growing electrophysiology (“EP”) manufacturing market; (2) despite Integer’s claims of strong visibility into customer demand, Integer was experiencing a sustained deterioration in sales relating to two of its EP devices; (3) in turn, Integer mischaracterized its EP devices as a long-term growth driver for its cardio and vascular (“C&V”) segment; (4) as a result of the above, defendants’ positive statements about Integer’s business, and operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Integer class action, go to https://rosenlegal.com/submit-form/?case_id=49170 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Envista (NVST - Free Report) reported $750.6 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 15%. EPS of $0.38 for the same period compares to $0.24 a year ago.

The reported revenue represents a surprise of +11.16% over the Zacks Consensus Estimate of $675.26 million. With the consensus EPS estimate being $0.32, the EPS surprise was +18.23%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Envista performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Sales- Equipment & Consumables: $274.7 million versus $248.55 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +13.5% change.Sales- Specialty Products & Technologies: $475.9 million compared to the $429.04 million average estimate based on four analysts. The reported number represents a change of +15.8% year over year.Adjusted Operating Profit- Equipment & Consumables: $55.2 million compared to the $52.56 million average estimate based on three analysts.Adjusted Operating Profit- Specialty Products & Technologies: $77 million compared to the $59.59 million average estimate based on three analysts.View all Key Company Metrics for Envista here>>>

Shares of Envista have returned +3.2% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Sun Country Airlines Holdings, Inc. (SNCY - Free Report) reported $280.96 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 7.9%. EPS of $0.17 for the same period compares to $0.27 a year ago.

The reported revenue represents a surprise of +2.71% over the Zacks Consensus Estimate of $273.56 million. With the consensus EPS estimate being $0.13, the EPS surprise was +36%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Sun Country Airlines performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Total System Statistics - Fuel cost per gallon: $2.56 versus the two-analyst average estimate of $2.55.Scheduled Service Statistics - Available seat miles (ASMs): 1.45 million versus the two-analyst average estimate of 1.47 million.Total System Statistics - Available seat miles (ASMs): 1.85 billion versus the two-analyst average estimate of 1.83 billion.Scheduled Service Statistics - Revenue passenger miles: 1.22 billion versus 1.23 billion estimated by two analysts on average.Scheduled Service Statistics - Load factor: 84.4% versus 83.8% estimated by two analysts on average.Total System Statistics - Fuel Gallons Consumed: 19.48 Mgal versus 19.47 Mgal estimated by two analysts on average.Total System Statistics - Adjusted CASM: 8.78 cents compared to the 9.39 cents average estimate based on two analysts.Operating Revenues- Passenger: $221.48 million versus $213.07 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +2.9% change.Operating Revenues- Other: $11.44 million versus $12.4 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -30.8% change.Operating Revenues- Cargo: $48.05 million versus $48.21 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +67.9% change.View all Key Company Metrics for Sun Country Airlines here>>>

Shares of Sun Country Airlines have returned +26.2% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

For the quarter ended December 2025, Encompass Health (EHC - Free Report) reported revenue of $1.54 billion, up 9.9% over the same period last year. EPS came in at $1.46, compared to $1.17 in the year-ago quarter.

The reported revenue represents a surprise of +0.23% over the Zacks Consensus Estimate of $1.54 billion. With the consensus EPS estimate being $1.29, the EPS surprise was +12.95%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Encompass Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net patient revenue per discharge: $22,273.00 versus $22,062.08 estimated by two analysts on average.Discharges: 67,238 versus 67,407 estimated by two analysts on average.Net Operating Revenues- Net patient revenue- Inpatient: $1.5 billion versus $1.49 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.6% change.View all Key Company Metrics for Encompass Health here>>>

Shares of Encompass Health have returned -10.1% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.